| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: DDDP |
| Security Type |
Common Stock |
| Lead Underwriter |
Bear Stearns & Co Inc |
| Days In Registration |
72 |
| Date Filed |
23-May-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company, focused on small-molecule drug discovery and development, via a pipeline of drug candidates in the areas of cancer, inflammation and metabolic and cardiovascular diseases |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
20.77M |
| CEO |
David C. U'Prichard, PhD |
| Number of Employees |
200 |
|
| Original Filing Information |
| US |
| Shares Filed |
4.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
4.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$56.0M |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
Current Filing Information
(Amended 3-Aug-2000) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$70.0M |
| · % Change from Original |
25.0 |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
|
